Study clarifies pathways in neuroendocrine differentiation in castration-resistant prostate cancer, suggesting new treatment options.
Aims Prostate cancer (PC) is a common male malignancy. Although androgen deprivation therapy (ADT) is standard for advanced PC, many patients develop castration-resistant PC (CRPC), and some progress to neuroendocrine PC (NEPC). This study aims to clarify mechanisms of this transition, especially the role of cancer stem cells (CSCs), and explore therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Shao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: